Product nameAnti-SAMHD1 antibody
See all SAMHD1 primary antibodies
DescriptionRabbit polyclonal to SAMHD1
Tested applicationsSuitable for: IP, WB, IHC-Pmore details
Species reactivityReacts with: Human
Synthetic peptide within Human SAMHD1 aa 450-500. The exact sequence is proprietary. NP_056289.2
Database link: Q9Y3Z3
- WB: HeLa and HEK-293T whole cell lysate. IP: HeLa whole cell lysate. IHC-P: Human ovarian carcinoma tissue.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab245389 was affinity purified using an epitope specific to SAMHD1 immobilized on solid support.
Our Abpromise guarantee covers the use of ab245389 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at 2-10 µg/mg of lysate.|
|WB||1/2000 - 1/10000. Predicted molecular weight: 72 kDa.|
|IHC-P||1/500 - 1/5000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionPutative nuclease involved in innate immune response by acting as a negative regulator of the cell-intrinsic antiviral response. May play a role in mediating proinflammatory responses to TNF-alpha signaling.
Tissue specificityExpressed in heart, skeletal muscle, spleen, liver, small intestine, placenta, lung and peripheral blood leukocytes. No expression is seen in brain and thymus.
Involvement in diseaseDefects in SAMHD1 are the cause of Aicardi-Goutieres syndrome type 5 (AGS5) [MIM:612952]. A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.
Sequence similaritiesBelongs to the SAMHD1 family.
Contains 1 HD domain.
Contains 1 SAM (sterile alpha motif) domain.
- Information by UniProt
- CHBL2 antibody
- DCIP antibody
- Dendritic cell derived IFNG induced protein antibody
All lanes : Anti-SAMHD1 antibody (ab245389) at 0.1 µg/ml
Lane 1 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 50 µg
Lane 4 : Jurkat (Human T cell leukemia cell line from peripheral blood) whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 72 kDa
Exposure time: 3 minutes
SAMHD1 was immunoprecipitated from HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate (1 mg per IP reaction; 20% of IP loaded).
ab245389 used for IP at 6 µg/mg lysate. For WB 1 µg/ml.
Lane 1: ab245389 IP in HeLa whole cell lysate.
Lane 2: Control IgG.
Chemiluminescence detection: 30 seconds.
Formalin-fixed, paraffin-embedded human ovarian carcinoma tissue stained for SAMHD1 with ab245389 at a 1/1000 dilution in immunohistochemical analysis. DAB staining. Counterstained using hematoxylin (blue).
ab245389 has not yet been referenced specifically in any publications.